Business Wire

Nido Biosciences Announces Publication of Collaborative Research Revealing Clinically Meaningful Endpoints for Spinal and Bulbar Muscular Atrophy

BOSTON--(BUSINESS WIRE)--Nido Biosciences (Nido Bio), a clinical stage company developing precision medicines for debilitating neurological diseases, today announced a new publication in Neurology ®, ...
Business Wire

Nido Biosciences Announces Orphan Drug Designation for Lead Clinical Candidate to Treat Spinal and Bulbar Muscular Atrophy

BOSTON--(BUSINESS WIRE)--Nido Biosciences (Nido Bio), a clinical stage company developing precision medicines for debilitating neurological diseases, announced today that the European Medicines Agency ...
Nasdaq

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of ...
Yahoo

What is bulbar ALS? WHO 13's Jeriann Ritter shares likely diagnosis

Add Yahoo as a preferred source to see more of our stories on Google. WHO 13 Meteorologist Jeriann Ritter says doctors believe she has amyotrophic lateral sclerosis, or ALS. Ritter explained how she's ...
The New England Journal of Medicine

Case 12-2019: A 60-Year-Old Man with Weakness and Difficulty Chewing

Dr. Amanda C. Guidon: A 60-year-old man was evaluated in the neurology clinic of this hospital because of weakness and difficulty chewing. Six months before this presentation, weakness developed in ...